News
Multi-Refractory MM: After Immunotherapy, What?
Experts outlined viable remaining options for treating multi-refractory myeloma, following immunotherapy.
News
Lymphoma Debate: CAR T Not a Clear Winner
Fiercely debating on best strategies for treating advanced lymphoma, specialists could not reach consensus.
News
Expert Updates Therapy for Waldenström Macroglobulinemia
A specialist applies a novel, nuanced approach to Waldenström macroglobulinemia, based on mutational status.
News
Phase 2 Data on New Drug Class for Prurigo Nodularis Promising
At 16 weeks, all povorcitinib doses were superior to placebo in achieving at least a 4-point reduction on the Itch Numerical Rating Scale and the...
News
Over 3 Years, Atopic Dermatitis Well-Controlled with Lebrikizumab
“Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.
News
Topical JAK Inhibitor Shows Benefits in Small Frontal Fibrosing Alopecia Study
The slow progress to identify treatments for FFA is illustrated by the fact that only one other double-blind and randomized trial has ever been...
News
Different Biomarker Profiles Identified in Study of Late Dupilumab Responders
A discovery that could lead to personalizing therapies, the data identified “distinct systemic biomarker profiles,” Ester Del Duca, MD, said.
News
Hidradenitis Suppurativa: Nodules Respond to As Needed Topical JAK Inhibitor
Entry criteria for the study included Hurley stage I or II HS with no draining tunnels. Hurley stage III patients were not eligible.
News
sNFl and sGFAP Predict MS Disability in Unique Ways
GFAP might soon join serum neurofilament light chain (sNFl) levels for predicting disability, but each has unique features and they appear to...
News
Childhood-Onset Atopic Dermatitis Adds Burden in Adulthood
The Scars of Life project was designed to analyze how the age of AD onset affects the severity of symptoms and quality of life.
News
Genetic Testing for ALS, Now a Standard, Creates a Path Toward Individualized Care
Overall, there is a sense of progress in ALS. The hope is that clinical research is reaching a tipping point where targeted treatments may offer...
News
Ofatumumab MS Study Supports Early Start Over Switch
New extension data from phase 3 ofatumumab RRMS study, show lower long-term disability accumulation with early-start of the more potent therapy...
News
Disability Reduction Is a Twist in Negative BTKi RRMS Trial
In phase 3 RRMS trials, tolebrutinib showed no advantage over teriflunomide for a relapse endpoint, but a disability endpoint advantage might...
News
Seborrheic Dermatitis in Black Patients: New Therapies Offer Hope
In patients with darker skin, the signs of seborrheic dermatitis can differ.